Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    No significant additions or deletions were detected on the page.
    Difference
    0.4%
    Check dated 2025-11-03T21:28:45.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    40 days ago
    Change Detected
    Summary
    Core content updated: replaces the mature T-cell/NK-cell non-Hodgkin lymphoma entry with malignant lymphoma, large B-cell, diffuse, and updates the revision/version to v3.2.0; adds a government operating-status notice. Overall meaning shifts from a previous lymphoma subtype listing to a broader large B-cell diffuse lymphoma entry and includes operational status information.
    Difference
    3%
    Check dated 2025-10-06T07:58:10.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    New version tag v3.1.0 added; one disease term 'Diffuse large b-cell lymphoma' removed. Overall, minimal impact on core content.
    Difference
    0.2%
    Check dated 2025-09-29T04:39:16.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' link.
    Difference
    0.2%
    Check dated 2025-09-14T22:14:10.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T19:21:20.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The web page has been updated to include new information on various types of lymphomas and a specific study related to pembrolizumab, while also removing several previous references to lymphoma types and location details.
    Difference
    6%
    Check dated 2025-08-31T12:27:30.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.